ID   CHLA-225
AC   CVCL_A057
DR   IARC_TP53; 23827
DR   Wikidata; Q54812189
RX   PubMed=11507071;
RX   PubMed=24792489;
CC   Doubling time: 62 hours (COG).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071).
ST   Source(s): COG
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,13
ST   D16S539: 11,13
ST   D18S51: 12,16
ST   D19S433: 13,16.2
ST   D21S11: 28,31.2
ST   D2S1338: 17,24
ST   D3S1358: 14,15
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 13,14
ST   FGA: 22,26
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Children
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 15
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//